Baricitinib restrains the immune dysregulation in patients with severe COVID-19

BACKGROUND: Patients with coronavirus disease 2019 (COVID-19) develop pneumonia generally associated with lymphopenia and a severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK/STAT signaling pathways, which can be disabled by...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Invest
Main Authors: Bronte, Vincenzo, Ugel, Stefano, Tinazzi, Elisa, Vella, Antonio, De Sanctis, Francesco, Canè, Stefania, Batani, Veronica, Trovato, Rosalinda, Fiore, Alessandra, Petrova, Varvara, Hofer, Francesca, Barouni, Roza Maria, Musiu, Chiara, Caligola, Simone, Pinton, Laura, Torroni, Lorena, Polati, Enrico, Donadello, Katia, Friso, Simonetta, Pizzolo, Francesca, Iezzi, Manuela, Facciotti, Federica, Pelicci, Pier Giuseppe, Righetti, Daniela, Bazzoni, Paolo, Rampudda, Mariaelisa, Comel, Andrea, Mosaner, Walter, Lunardi, Claudio, Olivieri, Oliviero
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Clinical Investigation 2020
נושאים:
Clinical Medicine
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8016181/
https://ncbi.nlm.nih.gov/pubmed/32809969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI141772
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים